Method of improving sleep

A technology for sleep, sleep disorders, applied in the treatment of patients with circadian rhythm sleep disorders, improving one or more sleep parameters of an individual, tasimelteon, one or more symptoms of the patient area, capable of addressing circadian rhythms and sleep/ Arousal cycle phenotypic differences and other issues

Pending Publication Date: 2022-01-28
VANDA PHARMA INC +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Variations in these genes may lead to differences in circadian rhythm and sleep / wake cycle phenotypes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of improving sleep
  • Method of improving sleep
  • Method of improving sleep

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] In a study of genetic variants associated with sleep-wake patterns, Applicants found a significant association between the rs184039278 CRY1 allele and the therapeutic efficacy of tasimelteon. Specifically, individuals with at least one copy of the rs184039278 CRY1 allele exhibit an improvement in one or more sleep parameters selected from the group consisting of: Persistent sleep latency (LPS ); sleep efficiency (%) during the first, second and / or last third of the night; rapid eye movement (REM) sleep duration; total sleep time (TST), including the first third During the night of II; and awakening after continuous sleep (WASO).

[0022] Table 1 below shows TST and sleep efficiency data for two individuals diagnosed with DSWPD and having at least one copy of the rs184039278 CRY1 allele who were administered 20 mg tasimelteon before bedtime. It can be seen that these individuals exhibit higher TST and sleep efficiency.

[0023] Table 1

[0024]

[0025] figure 1 T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of co-pending U.S. Provisional Patent Application Serial No. 62 / 805,057, filed February 13, 2019, which is hereby incorporated herein as if fully set forth. Background technique [0003] Circadian Rhythm and Sleep [0004] The timing of sleep in humans is controlled by two regulatory processes. The first - sleep homeostasis, which maintains a balance between awake time (during which fatigue accumulates) and sleep time (which is restorative and prepares the individual for the next awakening). The second - an endogenous rhythm regulated by a circadian pacemaker in the suprachiasmatic nucleus (SCN), which counteracts the effects of fatigue with signals from the circadian pacemaker. At night, when the homeostatic drive to sleep is high, the signals that promote wakefulness are at their peak. Then, as the individual approaches bedtime, the output of the SCN weakens and sleep ensues. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61P25/20C12Q1/6883
CPCA61K31/343A61P25/20C12Q1/6883C12Q2600/156C12Q2600/106
Inventor M·波利梅罗普洛斯S·斯迈斯泽克
Owner VANDA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap